A unifying model to explain nirmatrelvir / ritonavir's high efficacy during early treatment and low efficacy as post-exposure prophylaxis, and to predict viral rebound https://www.medrxiv.org/content/10.1101/2023.08.23.23294505
QOTO: Question Others to Teach Ourselves An inclusive, Academic Freedom, instance All cultures welcome. Hate speech and harassment strictly forbidden.